激素性青光眼的研究进展  

Research advances of glucocorticoid induced glaucoma

作　　者：姚乃成[1] 张虹[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院眼科,武汉430030

出　　处：《临床眼科杂志》2007年第5期470-473,共4页Journal of Clinical Ophthalmology

摘　　要：目的自激素性青光眼首次报道以来已有50多年,人们对于激素性青光眼的危险因素、发病机制和防治都有了进一步的了解。原发性开角型青光眼患者及其亲属,高度近视眼患者等对激素治疗引起的眼压增高较敏感。糖皮质激素主要是通过糖皮质激素受体发挥作用,使小梁网的细胞外基质沉积,增加房水流出阻力而导致眼压升高。进一步了解激素性青光眼的危险因素和发病机制可以有助于我们更好的预防和治疗激素性青光眼。Objective Corticosteroid-induced ocular hypertension and glaucoma has been recognized for more than 50 years The purpose of this article is to briefly review the literature of corticosteroid-induced ocular hypertension and glaucoma, its risk factors, the pathophysiology, and treatment options.. Primary open-angle glaucoma, excessive myopia and a family history of glaucoma are risk factors for an ocular hypertensive response with the use of corticosteroid therapy. The mechanism of elevated intraocular pressure is increased aqueous outflow resistance owing to an accumulation of extracellular matrix material in the trabecular meshwork by glucocorticoid receptor . Knowing the risk factors, prevalence, and patho-physiology can help the clinician prevent, and treat corticosteroid-induced glaucoma.

关 键 词：糖皮质激素 激素性青光眼 皮厅激素受体 小梁网 TIGR/MYOC 

分 类 号：R775[医药卫生—眼科]